{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"27.89","upperLimit":"45.47","value":"37.29"},{"groupId":"OG001","lowerLimit":"26.81","upperLimit":"39.03","value":"34.30"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"115"},{"groupId":"OG001","value":"116"}],"units":"Participants"}],"description":"OS was defined as the time from date of randomization to date of death due to any cause. If a patient was not known to have died, survival was censored at the date of last known date patient alive.\n\nThe OS distribution was estimated using Kaplan-Meier methodology.","dispersionType":"95% Confidence Interval","groups":[{"description":"Subjects with advanced breast cancer without a PIK3CA mutation (based on central testing of hotspot-mutations in tumor tissue) treated with alpelisib (300 mg; oral; once daily) in combination with fulvestrant (500 mg; intramuscular injection on Day 1 and Day 15 of Cycle 1, and then Day 1 of each subsequent 28-day cycle)","id":"OG000","title":"PIK3CA Non-mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant"},{"description":"Subjects with advanced breast cancer without a PIK3CA mutation (based on central testing of hotspot-mutations in tumor tissue) treated with placebo (300 mg; oral; once daily) in combination with fulvestrant (500 mg; intramuscular injection on Day 1 and Day 15 of Cycle 1, and then Day 1 of each subsequent 28-day cycle)","id":"OG001","title":"PIK3CA Non-mutant Cohort by Tumor Tissue: Placebo + Fulvestrant"}],"paramType":"MEDIAN","populationDescription":"All subjects without a PIK3CA mutation (based on central testing of hotspot-mutations in tumor tissue) who were randomized to study treatment","reportingStatus":"POSTED","timeFrame":"Up to 56.4 months","title":"OS in the PIK3CA Non-mutant Cohort","type":"SECONDARY","unitOfMeasure":"Months"}